Howard R, Zubko O, Bradley R, et al. - This study was conducted to ascertain whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild Alzheimer disease (AD). Between May 23, 2014, and April 14, 2016, individuals were included in a double-blind randomized clinical trial, with 24 months of treatment and follow-up. Thirty-two National Health Service memory clinics within secondary specialist services for people with dementia were included in England and Scotland. Researchers screened 886 individuals, 554 individuals with a diagnosis of mild AD (Standardised Mini-Mental State Examination [sMMSE] score ≥24) were randomized. In people with mild AD, minocycline did not delay the progress of cognitive or functional impairment during a 2-year period. This research also discovered that 400 mg of minocycline is poorly tolerated in this population.